] Filters: Author is Tetrud, J W [Clear All Filters]
Doostzadeh J, Tetrud JW, Allen-Auerbach M, Langston JW, Schüle B. Novel features in a patient homozygous for the L347P mutation in the PINK1 gene. Parkinsonism Relat Disord. 2007;13(6):359-61.
0
Tanner CM, Goldman SM, Lyons KE, Aston DA, Tetrud JW, Welsh MD, et al. Essential tremor in twins: an assessment of genetic vs environmental determinants of etiology. Neurology. 2001;57(8):1389-91.
Sobel N, Thomason ME, Stappen I, Tanner CM, Tetrud JW, Bower JM, et al. An impairment in sniffing contributes to the olfactory impairment in Parkinson's disease. Proc Natl Acad Sci USA. 2001;98(7):4154-9.
Snow BJ, Vingerhoets FJ, Langston JW, Tetrud JW, Sossi V, Calne DB. Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J Neurol Neurosurg Psychiatr. 2000;68(3):313-6.
Burkhard PR, Shale H, Langston JW, Tetrud JW. Quantification of dyskinesia in Parkinson's disease: validation of a novel instrumental method. Mov Disord. 1999;14(5):754-63.
Vingerhoets FJ, Snow BJ, Tetrud JW, Langston JW, Schulzer M, Calne DB. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol. 1994;36(5):765-70.
Tetrud JW, Langston JW, Irwin I, Snow B. Parkinsonism caused by petroleum waste ingestion. Neurology. 1994;44(6):1051-4.
Kurth MC, Tetrud JW, Tanner CM, Irwin I, Stebbins GT, Goetz CG, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology. 1993;43(9):1698-703.
Kurth MC, Tetrud JW, Irwin I, Lyness WH, Langston JW. Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study. Neurology. 1993;43(5):1036-9.
Tetrud JW, Langston JW. Protective and preventive therapeutic strategies: monoamine oxidase inhibitors. Neurologic clinics. 1992;10(2):541-52.
Bloem BR, Irwin I, Buruma OJ, Haan J, Roos RA, Tetrud JW, et al. The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease. J Neurol Sci. 1990;97(2-3):273-93.
Stern Y, Tetrud JW, Martin WR, Kutner SJ, Langston JW. Cognitive change following MPTP exposure. Neurology. 1990;40(2):261-4.
Kurth MC, Langston JW, Tetrud JW. "Stelazine" versus "selegiline"--a hazard in prescription writing. N Engl J Med. 1990;323(25):1776.
Tetrud JW, Langston JW, Garbe PL, Ruttenber AJ. Mild parkinsonism in persons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neurology. 1989;39(11):1483-7.
Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science. 1989;245(4917):519-22.
Tetrud JW, Langston JW. MPTP-induced parkinsonism as a model for Parkinson's disease. Acta Neurol Scand, Suppl. 1989;126:35-40.
Tetrud JW, Langston JW. R-(-)-deprenyl as a possible protective agent in Parkinson's disease. J Neural Transm Suppl. 1987;25:69-79.
Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology. 1985;35(7):949-56.
Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219(4587):979-80.